Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 18969037 | PRESSURIZED INHALATION COMPOSITION OF TIOTROPIUM | December 2024 | November 2025 | Allow | 11 | 2 | 0 | Yes | No |
| 18965257 | DRY POWDER ESKETAMINE COMPOSITION FOR USE IN THE TREATMENT OF BIPOLAR DEPRESSION BY PULMONARY ADMINISTRATION | December 2024 | September 2025 | Allow | 9 | 1 | 0 | Yes | No |
| 18486860 | VIP and VIP Agonists, Nanoparticles, and Uses in Inflammatory T-Cell Mediated Disease | October 2023 | March 2026 | Allow | 29 | 1 | 0 | Yes | No |
| 18282137 | COSMETIC PRODUCT WITH SURFACE DECORATION OF DYNAMIC IMAGES | September 2023 | February 2026 | Allow | 29 | 1 | 0 | No | No |
| 18465067 | POST-EMERGENCE HERBICIDE | September 2023 | February 2026 | Allow | 29 | 2 | 0 | No | No |
| 18233409 | ANTIMICROBIAL SILVER IODATE | August 2023 | March 2025 | Allow | 19 | 1 | 0 | Yes | No |
| 18446645 | CONTROLLING WATER RELEASE FROM A DIMENSIONALLY STABLE AQUEOUS COMPOSITION | August 2023 | June 2025 | Allow | 22 | 1 | 0 | Yes | No |
| 18361242 | METFORMIN INHALATION POWDER AEROSOL FOR TREATING IDIOPATHIC PULMONARY FIBROSIS AND PREPARATION METHOD THEREOF | July 2023 | December 2025 | Allow | 29 | 1 | 0 | No | No |
| 18346642 | KITS FOR MANUFACTURING INHALABLE FORMULATIONS OF MEDICINAL CANNABIS COMPOUNDS FOR AEROSOL DEVICES, APPARATUSES, AND METHODS FOR MAKING AND USING THE SAME | July 2023 | June 2025 | Abandon | 23 | 1 | 0 | No | No |
| 18217105 | TRANSDERMAL FORMULATION FOR THE TREATMENT OF PAIN AND/OR INFLAMMATION | June 2023 | April 2025 | Allow | 21 | 1 | 0 | No | No |
| 18201776 | PRESSED POWDER PRODUCT AND METHOD FOR PREPARING THE SAME | May 2023 | January 2026 | Allow | 32 | 1 | 0 | No | No |
| 18310647 | NASAL DELIVERY | May 2023 | April 2025 | Abandon | 24 | 1 | 0 | No | No |
| 18310311 | Nanostructured Gels Capable of Controlled Release of Encapsulated Agents | May 2023 | February 2025 | Abandon | 22 | 1 | 0 | No | No |
| 18307860 | ANTIMICROBIAL COMPOSITION | April 2023 | May 2025 | Allow | 24 | 2 | 0 | Yes | No |
| 18139031 | INHALABLE FORMULATION OF FLUTICASONE PROPIONATE AND ALBUTEROL SULFATE | April 2023 | February 2025 | Allow | 21 | 2 | 0 | Yes | No |
| 18033349 | METHOD FOR PREPARING ANTIMICROBIAL TREATMENT AGENT FOR TEXTILE | April 2023 | March 2026 | Allow | 35 | 2 | 0 | No | No |
| 18248056 | INHALATION FORMULATION, AND PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | April 2023 | February 2026 | Abandon | 35 | 0 | 1 | No | No |
| 18190614 | EUTECTIC SOLVENTS COMPRISING PHARMACEUTICAL AGENTS, AND METHODS OF MAKING AND USE THEREOF | March 2023 | June 2025 | Abandon | 27 | 2 | 0 | No | No |
| 18024821 | POWDER COMPOSITION BASED ON MICROPARTICLES EMBEDDING NANOPARTICLES FOR THE DELIVERY OF THERAPEUTIC/DIAGNOSTIC COMPOUNDS | March 2023 | March 2025 | Allow | 24 | 3 | 1 | Yes | No |
| 18116690 | METHODS AND COMPOSITIONS FOR ALTERING SECONDARY METABOLITES IN PLANTS | March 2023 | February 2025 | Abandon | 24 | 2 | 0 | No | No |
| 18113384 | POLYMERIC PARTICLES CONTAINING MICROORGANISMS | February 2023 | October 2024 | Allow | 20 | 1 | 0 | No | No |
| 18110273 | COMPOSITIONS AND METHODS FOR OPHTHALMIC AND/OR OTHER APPLICATIONS | February 2023 | June 2024 | Allow | 16 | 1 | 0 | Yes | No |
| 18106948 | Diketopiperazine Microparticles with Defined Specific Surface Areas | February 2023 | May 2025 | Allow | 27 | 4 | 0 | No | No |
| 18153096 | AEROSOL FORMULATION FOR COPD | January 2023 | March 2025 | Allow | 26 | 2 | 1 | Yes | No |
| 18015577 | A POLYHERBAL METALLO-MINERAL PHARMACEUTICAL KIT | January 2023 | December 2025 | Allow | 35 | 2 | 0 | Yes | No |
| 18145471 | Systems, Methods and Products for Minimizing Tissue Reactions and Tissue Injury at an Infusion Site | December 2022 | June 2024 | Allow | 17 | 1 | 0 | No | No |
| 18011770 | MULTI-LAYERED MEDICAMENT FOR INHALATION | December 2022 | September 2025 | Allow | 33 | 1 | 0 | No | No |
| 18075627 | THERAPEUTIC AGENT DELIVERY SYSTEMS AND METHODS OF FORMING AND USES THEREOF | December 2022 | October 2025 | Abandon | 35 | 1 | 0 | No | No |
| 18057486 | DELIVERY DEVICE AND FORMULATION | November 2022 | April 2024 | Allow | 17 | 1 | 0 | No | No |
| 17988263 | ENGINEERED METAL NANOPARTICLES AND METHODS THEREOF | November 2022 | November 2024 | Abandon | 24 | 2 | 0 | No | No |
| 17998308 | NOVEL INHALANT | November 2022 | October 2025 | Abandon | 35 | 1 | 0 | No | No |
| 17976737 | DIMETHYL SULFOXIDE (DMSO) AND METHYLSULFONYLMETHANE (MSM) FORMULATIONS TO TREAT OSTEOARTHRITIS | October 2022 | June 2024 | Abandon | 19 | 1 | 0 | No | No |
| 17972435 | EXTENDED RELEASE MULTIPARTICULATES OF RANOLAZINE | October 2022 | July 2024 | Allow | 21 | 2 | 0 | No | No |
| 17963176 | Peramivir Dry Powder Inhaler and Method of Preparing the Same | October 2022 | February 2026 | Abandon | 40 | 1 | 0 | No | No |
| 17936560 | FUNGICIDAL COMBINATIONS | September 2022 | April 2025 | Allow | 31 | 3 | 0 | Yes | No |
| 17911523 | TREATMENT WITH POWDERED INTRANASAL EPINEPHRINE | September 2022 | March 2026 | Allow | 42 | 2 | 0 | No | No |
| 17906241 | GOLD-CONTAINING AGENTS FOR THE TREATMENT OF LUNG INFECTIONS | September 2022 | November 2025 | Allow | 38 | 2 | 0 | Yes | No |
| 17823336 | MONOCLONAL ANTIBODY DRY POWDERS | August 2022 | May 2025 | Abandon | 32 | 2 | 1 | No | No |
| 17893612 | COMPOSITIONS AND METHODS FOR TREATING PULMONARY EDEMA OR LUNG INFLAMMATION | August 2022 | September 2023 | Allow | 13 | 1 | 0 | No | No |
| 17886124 | Inhalable Epinephrine Formulation | August 2022 | March 2024 | Allow | 19 | 3 | 0 | Yes | No |
| 17885487 | NOVEL AEROSOL FORMULATIONS OF ONDANSETRON AND USES THEREOF | August 2022 | December 2023 | Abandon | 16 | 1 | 0 | No | No |
| 17882132 | COMPOSITIONS AND METHODS FOR ENHANCING TRANSPORT THROUGH MUCUS | August 2022 | November 2023 | Abandon | 15 | 1 | 0 | No | No |
| 17877937 | ANTIHISTAMINE AND ANTI-MICROBIAL NASAL SOLUTIONS AND RELATED METHODS | July 2022 | July 2024 | Abandon | 24 | 2 | 0 | No | No |
| 17816207 | FLEXIBLE COLOR SUBSTATE | July 2022 | July 2024 | Allow | 24 | 2 | 1 | Yes | No |
| 17816220 | BONDABLE MICROCAPSULES AND SURFACE FUNCTIONALIZED FILLERS | July 2022 | August 2023 | Allow | 12 | 1 | 0 | Yes | No |
| 17871232 | NASAL HYGIENE COMPOSITIONS, ANTIMICROBIAL TREATMENTS, DEVICES, AND ARTICLES FOR DELIVERY OF SAME TO THE NOSE, TRACHEA AND MAIN BRONCHI | July 2022 | September 2024 | Abandon | 26 | 2 | 0 | Yes | No |
| 17861072 | COMPOSITIONS, METHODS AND SYSTEMS FOR AEROSOL DRUG DELIVERY | July 2022 | March 2024 | Abandon | 20 | 3 | 0 | Yes | No |
| 17810941 | POST-EMERGENCE HERBICIDE | July 2022 | September 2023 | Abandon | 15 | 1 | 0 | No | No |
| 17834583 | INTRANASAL DHE FOR THE TREATMENT OF HEADACHE | June 2022 | December 2025 | Allow | 42 | 4 | 0 | Yes | No |
| 17744333 | Transdural Drug Delivery System | May 2022 | February 2024 | Abandon | 21 | 4 | 1 | Yes | No |
| 17737434 | INHALABLE PARTICLES | May 2022 | July 2023 | Allow | 14 | 1 | 0 | Yes | No |
| 17724474 | Lung-targeted corticosteroid treatment in viral respiratory disease, COVID-19 and ARDS (acute respiratory distress syndrome) | April 2022 | September 2024 | Abandon | 29 | 2 | 1 | No | No |
| 17699405 | LOW-DOSE BRIMONIDINE COMBINATIONS AND USES THEREOF | March 2022 | December 2025 | Abandon | 45 | 5 | 0 | No | No |
| 17695155 | Inhalable dry powder pharmaceutical composition | March 2022 | January 2024 | Abandon | 22 | 0 | 1 | No | No |
| 17694056 | METHOD FOR CULTIVATING CITRUS PLANT | March 2022 | June 2025 | Abandon | 39 | 4 | 0 | Yes | No |
| 17694101 | METHOD FOR CULTIVATING CITRUS PLANT AND LIQUID COMPOSITION | March 2022 | May 2025 | Abandon | 38 | 4 | 0 | Yes | No |
| 17685704 | NEBULIZED IMATINIB FORMULATIONS, MANUFACTURE, AND USES THEREOF | March 2022 | March 2025 | Abandon | 37 | 2 | 1 | No | Yes |
| 17590051 | LIPOPHILIC COSMETIC COMPOSITIONS CONTAINING PELARGONIC ACID ESTERS | February 2022 | June 2024 | Allow | 28 | 2 | 0 | No | No |
| 17574052 | HERBICIDAL COMBINATION | January 2022 | September 2023 | Abandon | 20 | 0 | 1 | No | No |
| 17547635 | METHOD OF USING COMPOSITION FOR TREATMENT OF VEISALGIA | December 2021 | April 2024 | Abandon | 28 | 2 | 0 | No | No |
| 17456271 | BUFFERED MICROENCAPSULATED COMPOSITIONS AND METHODS | November 2021 | August 2023 | Allow | 21 | 2 | 0 | No | No |
| 17595463 | FUNCTIONAL FIBROUS MATERIAL COMPRISING MICROBIAL FLAKES, METHODS OF PREPARING AND USES THEREOF | November 2021 | July 2025 | Allow | 44 | 2 | 0 | Yes | No |
| 17528011 | INHALED IMATINIB FOR PULMONARY HYPERTENSION | November 2021 | March 2026 | Abandon | 52 | 4 | 1 | Yes | Yes |
| 17611746 | CHEMICAL COMPOSITION FOR SEED TREATMENT | November 2021 | August 2025 | Allow | 45 | 2 | 0 | Yes | No |
| 17523229 | POWDER INJECTION OF THE DONEPEZIL SEMI PALMOXIRIC ACID SALT, COMPOSITION CONTAINING SAME AND PREPARATION METHOD THEREFOR | November 2021 | July 2023 | Allow | 20 | 1 | 0 | Yes | No |
| 17517157 | Composition of a Spray-Dried Powder for Pulmonary Delivery of a Long Acting Neuraminidase Inhibitor (LANI) | November 2021 | March 2024 | Abandon | 29 | 1 | 1 | No | No |
| 17506190 | Methods and Compositions for Spray Drying Gram-Negative Bacteria | October 2021 | October 2024 | Abandon | 35 | 3 | 0 | Yes | No |
| 17494885 | ANTIMICROBIAL COMPOSITION | October 2021 | December 2023 | Abandon | 26 | 2 | 0 | No | No |
| 17489128 | LINEAR POLYSACCHARIDE BASED FILM PRODUCTS | September 2021 | December 2025 | Allow | 50 | 5 | 0 | Yes | No |
| 17439385 | PHARMACEUTICAL DOSAGE FORM FOR APPLICATION TO MUCOUS MEMBRANES AND METHODS FOR PRODUCING SAME | September 2021 | May 2025 | Allow | 44 | 2 | 0 | Yes | No |
| 17470788 | TRANSDERMAL FORMULATION FOR THE TREATMENT OF PAIN AND/OR INFLAMMATION | September 2021 | March 2023 | Allow | 18 | 1 | 0 | No | No |
| 17465911 | DISINFECTANT-DOSING MICROGEL AND METHOD OF USING THE SAME | September 2021 | August 2025 | Abandon | 48 | 2 | 1 | No | No |
| 17465126 | EXPANDABLE MICROCAPSULE | September 2021 | November 2024 | Abandon | 38 | 1 | 0 | No | No |
| 17410774 | Inhalable Formulation of Fluticasone Propionate and Albuterol Sulfate | August 2021 | January 2023 | Allow | 17 | 3 | 1 | Yes | No |
| 17405773 | LOW-DOSE BRIMONIDINE COMBINATIONS AND USES THEREOF | August 2021 | December 2025 | Abandon | 52 | 5 | 0 | No | No |
| 17400897 | ANTIMICROBIAL SILVER IODATE | August 2021 | May 2023 | Allow | 21 | 2 | 0 | No | No |
| 17392824 | METHODS AND MATERIALS FOR TREATING LUNG DISORDERS | August 2021 | August 2024 | Allow | 36 | 3 | 0 | Yes | No |
| 17371603 | NON-THERAPEUTIC METHOD, USES OF A SUBSTANCE THAT STIMULATES OR GENERATES AN INCREASE IN VOLUME | July 2021 | July 2023 | Abandon | 25 | 1 | 0 | No | No |
| 17352076 | Disinfection Composition and Preparation Method Therefor and Use Thereof | June 2021 | July 2022 | Allow | 13 | 2 | 1 | Yes | No |
| 17345830 | METHOD OF USING NEBULIZED ALCOHOL FOR ANALGESIA | June 2021 | August 2022 | Allow | 14 | 2 | 0 | No | No |
| 17311153 | Oral Thin Films | June 2021 | October 2025 | Allow | 52 | 4 | 1 | Yes | No |
| 17330485 | DELIVERY OF AEROSOLIZED MICROMOLAR COMPOSITION CONCENTRATIONS | May 2021 | May 2023 | Abandon | 24 | 3 | 0 | No | Yes |
| 17327268 | 4% Trisodium Citrate Solution for Use as a Catheter Lock Solution | May 2021 | August 2025 | Allow | 51 | 2 | 0 | Yes | Yes |
| 17292226 | NEW COMPOSITION COMPRISING AMORPHOUS NANOPOROUS SILICA PARTICLES | May 2021 | December 2023 | Abandon | 31 | 0 | 1 | No | No |
| 17290585 | SOLID COMPOSITION FOR PLANT CARE CONTAINING FUNGAL SCLEROTIA AND USE THEREOF | April 2021 | June 2025 | Abandon | 50 | 2 | 1 | No | No |
| 17244455 | MULTI-PURPOSE LIGNIN-CARBOHYDRATE BINDING SYSTEM | April 2021 | June 2025 | Allow | 49 | 5 | 1 | Yes | Yes |
| 17237350 | Combinations of Glycopyrrolate and Beta2 Adrenoceptor Agonists | April 2021 | June 2023 | Abandon | 25 | 1 | 0 | No | No |
| 17221645 | COMPOSITIONS COMPRISING A MANGANESE MINERAL AND METHODS OF USE | April 2021 | June 2023 | Allow | 26 | 2 | 0 | Yes | Yes |
| 17281399 | FORMULATION AND AEROSOL CANISTERS, INHALERS, AND THE LIKE CONTAINING THE FORMULATION | March 2021 | May 2024 | Abandon | 38 | 2 | 1 | No | No |
| 17281136 | KETAMINE COMPOSITION FOR USE IN A METHOD OF TREATMENT OF DEPRESSION BY PULMONARY ADMINISTRATION | March 2021 | November 2023 | Allow | 31 | 1 | 1 | Yes | No |
| 17215249 | N-MYC-INTERACTOR PROTEIN AS A MARKER FOR CHRONIC LUNG DISEASE AND USES THEREOF | March 2021 | November 2023 | Allow | 31 | 1 | 1 | Yes | No |
| 17214416 | AEROSOLIZED FLUOROQUINOLONES AND USES THEREOF | March 2021 | May 2023 | Abandon | 26 | 1 | 0 | No | No |
| 17280452 | PHARMACEUTICAL COMPOSITIONS COMPRISING RPL554 IN HFA-134A FOR ADMINISTRATION BY INHALATION | March 2021 | April 2024 | Abandon | 36 | 3 | 0 | No | No |
| 17207442 | COMPOSITIONS AND METHODS FOR OPHTHALMIC AND/OR OTHER APPLICATIONS | March 2021 | September 2021 | Allow | 6 | 1 | 0 | No | No |
| 17207467 | COMPOSITIONS AND METHODS FOR OPHTHALMIC AND/OR OTHER APPLICATIONS | March 2021 | September 2021 | Allow | 6 | 1 | 0 | No | No |
| 17205304 | SEED PRE-SOAK TECHNOLOGY WITH A DROP OF HEMATITE NANOPARTICLE FERTILIZER FOR INCREASED PLANT GROWTH | March 2021 | June 2025 | Allow | 51 | 3 | 1 | Yes | No |
| 17275086 | PHARMACEUTICAL COMPOSITION OF CHLORINE FOR TREATMENT OF RESPIRATORY VIRAL INFECTION | March 2021 | September 2024 | Abandon | 43 | 4 | 0 | No | No |
| 17192764 | METHODS OF MULTI-SPECIES INSECT PEST CONTROL | March 2021 | November 2024 | Allow | 44 | 2 | 1 | Yes | No |
| 17186561 | Inhalable Formulation of a Solution Containing Glycopyrronium Bromide | February 2021 | June 2022 | Abandon | 15 | 2 | 0 | Yes | No |
| 17269642 | CANNABINOID-CONTAINING PRODUCTS, CONTAINERS, SYSTEMS, AND METHODS | February 2021 | October 2024 | Abandon | 44 | 0 | 1 | No | No |
This analysis examines appeal outcomes and the strategic value of filing appeals for examiner HAGHIGHATIAN, MINA.
With a 25.0% reversal rate, the PTAB affirms the examiner's rejections in the vast majority of cases. This reversal rate is below the USPTO average, indicating that appeals face more challenges here than typical.
Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.
In this dataset, 13.4% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is in the bottom 25% across the USPTO, indicating that filing appeals is less effective here than in most other areas.
⚠ Appeals to PTAB face challenges. Ensure your case has strong merit before committing to full Board review.
⚠ Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.
Examiner HAGHIGHATIAN, MINA works in Art Unit 1616 and has examined 1,262 patent applications in our dataset. With an allowance rate of 50.8%, this examiner allows applications at a lower rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 32 months.
Examiner HAGHIGHATIAN, MINA's allowance rate of 50.8% places them in the 13% percentile among all USPTO examiners. This examiner is less likely to allow applications than most examiners at the USPTO.
On average, applications examined by HAGHIGHATIAN, MINA receive 2.43 office actions before reaching final disposition. This places the examiner in the 70% percentile for office actions issued. This examiner issues a slightly above-average number of office actions.
The median time to disposition (half-life) for applications examined by HAGHIGHATIAN, MINA is 32 months. This places the examiner in the 49% percentile for prosecution speed. Prosecution timelines are slightly slower than average with this examiner.
Conducting an examiner interview provides a +22.6% benefit to allowance rate for applications examined by HAGHIGHATIAN, MINA. This interview benefit is in the 68% percentile among all examiners. Recommendation: Interviews provide an above-average benefit with this examiner and are worth considering.
When applicants file an RCE with this examiner, 19.3% of applications are subsequently allowed. This success rate is in the 19% percentile among all examiners. Strategic Insight: RCEs show lower effectiveness with this examiner compared to others. Consider whether a continuation application might be more strategic, especially if you need to add new matter or significantly broaden claims.
This examiner enters after-final amendments leading to allowance in 31.2% of cases where such amendments are filed. This entry rate is in the 45% percentile among all examiners. Strategic Recommendation: This examiner shows below-average receptiveness to after-final amendments. You may need to file an RCE or appeal rather than relying on after-final amendment entry.
When applicants request a pre-appeal conference (PAC) with this examiner, 50.0% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 42% percentile among all examiners. Note: Pre-appeal conferences show below-average success with this examiner. Consider whether your arguments are strong enough to warrant a PAC request.
This examiner withdraws rejections or reopens prosecution in 53.8% of appeals filed. This is in the 25% percentile among all examiners. Of these withdrawals, 66.1% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner rarely withdraws rejections during the appeal process compared to other examiners. If you file an appeal, be prepared to fully prosecute it to a PTAB decision. Per MPEP § 1207, the examiner will prepare an Examiner's Answer maintaining the rejections.
When applicants file petitions regarding this examiner's actions, 52.4% are granted (fully or in part). This grant rate is in the 52% percentile among all examiners. Strategic Note: Petitions show above-average success regarding this examiner's actions. Petitionable matters include restriction requirements (MPEP § 1002.02(c)(2)) and various procedural issues.
Examiner's Amendments: This examiner makes examiner's amendments in 8.5% of allowed cases (in the 91% percentile). Per MPEP § 1302.04, examiner's amendments are used to place applications in condition for allowance when only minor changes are needed. This examiner frequently uses this tool compared to other examiners, indicating a cooperative approach to getting applications allowed. Strategic Insight: If you are close to allowance but minor claim amendments are needed, this examiner may be willing to make an examiner's amendment rather than requiring another round of prosecution.
Quayle Actions: This examiner issues Ex Parte Quayle actions in 1.2% of allowed cases (in the 63% percentile). This examiner issues Quayle actions more often than average when claims are allowable but formal matters remain (MPEP § 714.14).
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.